AUTL Autolus Therapeutics ADS

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023.

Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the of Autolus’ website.

Contact:

Julia Wilson

+44 (0) 7818 430877

Susan A. Noonan

S.A. Noonan Communications



Lauren Williams

Investase

0



EN
11/10/2023

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

Jacob Mekhael
  • Jacob Mekhael
AUTL Autolus Therape...

Autolus 1Q25 shows higher than expected Aucatzyl sales in r/r adult AL...

Yesterday before US market open, Autolus reported 1Q25 results with the highlight being the first Aucatzyl (CD19 CAR-T) sales in r/r adult ALL in the US ($ 9m), coming in above our expectations (1Q25 KBCSe $ 5m) and sending the stock up +10%. We see the stronger than expected initial demand as a good sign for the remainder of the launch. Seasonality remains to be seen, but if this momentum continues for the rest of FY25, our sales estimate of $ 43m will be within reach (BBG CSS $ 37m). We reiter...

AUTL AUTOLUS THERAPEUTICS ADS
05/09/25 May 9, 2025 1 EN
Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Lynn Hautekeete
  • Michiel Declercq
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
PROX Proximus SA de ...
UCB UCB S.A. ... (+10)

Morning Notes : AED BB, BPOST BB, COFB BB, MONT BB, ONTEX BB, PROX BB,...

: AED BB, BPOST BB, COFB BB, MONT BB, ONTEX BB, PROX BB, UCB BB, VGP BB, AUTL US, ECMPA NA

PROX PROXIMUS SA DE DROIT PUBLIC
UCB UCB S.A.
COFB COFINIMMO SA
MONT MONTEA SCA
AED AEDIFICA SA
BPOST BPOST SA
ONTEX ONTEX GROUP N.V.
VGP VGP NV
AUTL AUTOLUS THERAPEUTICS ADS
ECMPA EUROCOMMERCIAL PROPERTIES NV
05/09/25 May 9, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Reports First Quarter 2025 Financial Results and ...

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 millionU.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in pr...

May 8, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
AUTL Autolus Therape...

Autolus Aucatzyl secures UK MHRA approval in r/r adult ALL, all eyes o...

Last Friday evening, Autolus announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for Aucatzyl (CD19 CAR-T) in adult relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), in line with the expected timeline. Looking ahead, Autolus will report its 1Q25 results on 8 May, where the first quarter US sales of Aucatzyl will be reported and will give us a quantitative view on the launch momentum – note that ...

AUTL AUTOLUS THERAPEUTICS ADS
04/28/25 April 28, 2025 1 EN
Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
TWEKA TKH GROUP N.V. CERT
MRUS MERUS B V
ARGX ARGEN-X SE
AUTL AUTOLUS THERAPEUTICS ADS
AKZA AKZO NOBEL N.V.
DEME DEME GROUP NV
04/28/25 April 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch